Literature DB >> 21051973

Primary versus interval debulking surgery in advanced ovarian cancer: results from a systematic single-center analysis.

Jalid Sehouli1, Konstantinos Savvatis, Elena-Ioana Braicu, Sven-Christian Schmidt, Werner Lichtenegger, Christina Fotopoulou.   

Abstract

OBJECTIVE: To evaluate the difference in operative and clinical outcome for patients with primary advanced ovarian cancer (AOC) after optimal primary debulking surgery (PDS) versus interval debulking surgery (IDS).
METHODS: Tumor dissemination pattern and surgical outcome, as defined by morbidity, progression-free (PFS) survival and overall survival (OS) were systematically analyzed in AOC patients who underwent surgery in our institution between September 2000 and August 2009. Overall survival and PFS were calculated by Kaplan-Meier curves. Univariate and Cox regression analysis were performed to identify the impact of IDS on surgical outcome and survival.
RESULTS: Overall, 372 consecutive patients with histologically proven AOC (FIGO [International Federation of Gynecology and Obstetrics] stage III/IV) were evaluated. Forty patients (10.8%) underwent IDS after a median of 5 cycles (range, 2-6 cycles) platinum- and taxane-based chemotherapy, and 332 patients (89.2%) underwent PDS. Patients who underwent IDS had a significantly lower rate of tumor involvement of the lower (78.9% vs 98.8%; P < 0.001) and middle abdomen (68.4% vs 83.1%; P = 0.044) compared with PDS patients. During IDS, a significantly higher probability for complete tumor resection occurred when compared with PDS (85% vs 58.7%; P = 0.02) by equivalent rates of operative complications (36.4% vs 36.5%; P = 1.00). However, mean PFS was significantly reduced in IDS patients (14.6 vs 33.2 months; P < 0.001). Mean OS was also higher in PDS patients, but this reached a statistical significance only when complete tumor resection was obtained (65.4 vs 37.9 months; P = 0.005). Multivariate analysis identified that IDS was associated with an unfavorable OS and PFS.
CONCLUSIONS: : It seems that PDS has a more favorable outcome than IDS on both OS and PFS in AOC patients, even though IDS leads to significantly higher rates of complete tumor resection.

Entities:  

Mesh:

Year:  2010        PMID: 21051973     DOI: 10.1111/IGC.0b013e3181f15714

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  16 in total

1.  S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.

Authors:  U Wagner; P Harter; F Hilpert; S Mahner; A Reuß; A du Bois; E Petru; W Meier; P Ortner; K König; K Lindel; D Grab; P Piso; O Ortmann; I Runnebaum; J Pfisterer; D Lüftner; N Frickhofen; F Grünwald; B O Maier; J Diebold; S Hauptmann; F Kommoss; G Emons; B Radeleff; M Gebhardt; N Arnold; G Calaminus; I Weisse; J Weis; J Sehouli; D Fink; A Burges; A Hasenburg; C Eggert
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-09       Impact factor: 2.915

Review 2.  Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.

Authors:  Shaun Hiu; Andrew Bryant; Ketankumar Gajjar; Patience T Kunonga; Raj Naik
Journal:  Cochrane Database Syst Rev       Date:  2022-08-30

Review 3.  The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review.

Authors:  Aditi Bhatt; Olivier Glehen
Journal:  Indian J Surg Oncol       Date:  2016-02-16

4.  Surgery for relapsed ovarian cancer: when should it be offered?

Authors:  Philipp Harter; Florian Heitz; Andreas du Bois
Journal:  Curr Oncol Rep       Date:  2012-12       Impact factor: 5.075

5.  Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers.

Authors:  E-I Braicu; J Sehouli; R Richter; K Pietzner; C Denkert; C Fotopoulou
Journal:  Br J Cancer       Date:  2011-11-01       Impact factor: 7.640

Review 6.  Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction.

Authors:  Mackenzie Cummings; Olivia Nicolais; Mark Shahin
Journal:  Diagnostics (Basel)       Date:  2022-04-14

7.  Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer.

Authors:  Marianne J Rutten; Gabe S Sonke; Anneke M Westermann; Willemien J van Driel; Johannes W Trum; Gemma G Kenter; Marrije R Buist
Journal:  Obstet Gynecol Int       Date:  2015-05-27

8.  A meta-analysis: neoadjuvant chemotherapy versus primary surgery in ovarian carcinoma FIGO stageIII and IV.

Authors:  Ma Dai-yuan; Tan Bang-xian; Li Xian-fu; Zhou Ye-qin; Cai Hong-Wei
Journal:  World J Surg Oncol       Date:  2013-10-10       Impact factor: 2.754

9.  The serum glycome to discriminate between early-stage epithelial ovarian cancer and benign ovarian diseases.

Authors:  Karina Biskup; Elena Iona Braicu; Jalid Sehouli; Rudolf Tauber; Véronique Blanchard
Journal:  Dis Markers       Date:  2014-08-12       Impact factor: 3.434

10.  HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer - a study of the OVCAD Consortium.

Authors:  Elena Ioana Braicu; Hrvoje Luketina; Rolf Richter; Dan Cacsire Castillo-Tong; Sandrina Lambrechts; Sven Mahner; Nicole Concin; Monika Mentze; Robert Zeillinger; Ignace Vergote; Jalid Sehouli
Journal:  Onco Targets Ther       Date:  2014-09-11       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.